Literature DB >> 27226065

De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.

Hakmin Lee1, Sang Eun Lee2, Seok-Soo Byun2, Hyeon Hoe Kim3, Cheol Kwak3, Sung Kyu Hong2.   

Abstract

OBJECTIVE: To evaluate the associations of preoperative De Ritis ratio (aspartate transaminase [AST]/alanine transaminase [ALT]) with postoperative clinical outcomes after surgical treatment of localized RCC.
MATERIALS AND METHODS: We retrospectively reviewed data from 2 965 patients surgically treated for non-metastatic RCC. Propensity scores for high AST/ALT ratio were calculated and 430 patients with a high AST/ALT ratio were matched to 1 117 patients with a low AST/ALT ratio. The association between AST/ALT ratio and postoperative outcomes was tested. Multivariate Cox analyses were performed to identify the independent predictors of progression-free (PFS), overall (OS) and cancer-specific survival (CSS).
RESULTS: According to the receiver-operating curve of AST/ALT for cancer-specific mortality, we stratified the patients into two groups using a threshold of 1.5. Before matching, patients with a high AST/ALT ratio had worse PFS, OS and CSS (all P < 0.001). In the propensity score-matched cohort with 1 547 patients, patients with a high AST/ALT ratio had inferior PFS, OS and CSS outcomes (all P < 0.001). Multivariate analysis showed that a high AST/ALT ratio was an independent predictor of disease progression (hazard ratio [HR] 1.372, 95% CI 1.003-1.882; P = 0.048), overall mortality (HR 1.559, 95% CI 1.069-2.272; P = 0.021), and cancer-specific mortality (HR 1.974, 95% CI 1.250-3.118; P = 0.004). In a subgroup analysis according to tumour histology, high AST/ALT had a significant association with postoperative survival in clear-cell renal cell carcinoma (RCC), but not in non-clear-cell RCC.
CONCLUSION: An elevated AST/ALT ratio was significantly associated with worse postoperative survival in patients surgically treated for localized clear-cell RCC. Further prospective studies are needed to understand the prognostic value of preoperative AST/ALT ratio.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  AST/ALT; prognosis; renal cell carcinoma; survival

Mesh:

Substances:

Year:  2016        PMID: 27226065     DOI: 10.1111/bju.13545

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  27 in total

1.  The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.

Authors:  Huitao Wang; Kewei Fang; Jinsong Zhang; Yongming Jiang; Guang Wang; Haiyan Zhang; Tao Chen; Xin Shi; Yuhang Li; Fei Duan; Jianhe Liu
Journal:  Int Urol Nephrol       Date:  2017-05-26       Impact factor: 2.370

2.  The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.

Authors:  Sacit Nuri Gorgel; Osman Kose; Esra Meltem Koc; Erhan Ates; Yigit Akin; Yuksel Yilmaz
Journal:  Int Urol Nephrol       Date:  2017-07-01       Impact factor: 2.370

3.  Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma.

Authors:  Burak Arslan; Okan Gürkan; Bugra Çetin; Öykü Aksoy Arslan; Taha Göv; Gökhan Yazıcı; Tolga Eroglu; Mustafa Asım Avcı; Enver Ozdemir
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

4.  The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma.

Authors:  Yang Hyun Cho; Jun Eul Hwang; Ho Seok Chung; Myung Soo Kim; Eu Chang Hwang; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Seock Hwan Choi; Hyun Tae Kim; Tae-Hwan Kim; Tae Gyun Kwon; Joon Hwa Noh; Myung Ki Kim; Chul-Sung Kim; Sung Gu Kang; Seok Ho Kang; Jun Cheon; Chan Ho Lee; Ja Yoon Ku; Hong Koo Ha; Bum Sik Tae; Chang Wook Jeong; Ja Hyeon Ku; Cheol Kwak; Hyeon Hoe Kim
Journal:  Int Urol Nephrol       Date:  2017-05-08       Impact factor: 2.370

5.  Influence of Preoperative Serum Aspartate Aminotransferase (AST) Level on the Prognosis of Patients with Non-Small Cell Lung Cancer.

Authors:  Shu-Lin Chen; Ning Xue; Mian-Tao Wu; Hao Chen; Xia He; Jian-Pei Li; Wan-Li Liu; Shu-Qin Dai
Journal:  Int J Mol Sci       Date:  2016-09-03       Impact factor: 5.923

6.  Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment.

Authors:  Minyong Kang; Seung Jea Shin; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Soo Jeon; Hyun Moo Lee; Seong Il Seo
Journal:  Dis Markers       Date:  2020-07-04       Impact factor: 3.434

7.  The Preoperative Predictive Factors for Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma.

Authors:  Shinji Fukui; Makito Miyake; Kota Iida; Kenta Onishi; Shunta Hori; Yosuke Morizawa; Yoriaki Kagebayashi; Kiyohide Fujimoto
Journal:  Diagnostics (Basel)       Date:  2019-07-15

8.  De Ritis ratio (AST/ALT) as an independent predictor of poor outcome in patients with acute ischemic stroke.

Authors:  Fan Gao; Chen Chen; Jun Lu; Jie Zheng; Xian-Cang Ma; Xing-Yun Yuan; Kang Huo; Jian-Feng Han
Journal:  Neuropsychiatr Dis Treat       Date:  2017-06-15       Impact factor: 2.570

9.  The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma.

Authors:  Lütfi Canat; Hasan Anil Ataly; Samir Agalarov; Ilter Alkan; Fatih Altunrende
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

10.  The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma.

Authors:  Sung Han Kim; Eun Young Park; Jungnam Joo; Jinsoo Chung
Journal:  J Oncol       Date:  2018-12-18       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.